Array Technologies Inc (ARRY): Ipatasertib / GDC-0068 Target: AKT |...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	481
Posts	60441
Boards Moderated	18
Alias Born	09/20/2001

XenaLives

Re: None

Monday, 03/20/2017 8:40:36 AM

Monday, March 20, 2017 8:40:36 AM

Ipatasertib / GDC-0068
Target: AKT | Indication: Solid Tumors

Introduction / Brief Description
Ipatasertib is an AKT inhibitor invented by Array under a collaboration agreement with Genentech. Array has received certain clinical milestones and is entitled to additional potential clinical and commercial milestones and royalties on product sales under the agreement.

AKT activity is frequently elevated in cancer via multiple mechanisms, including loss of function of the PTEN tumor suppressor gene or mutations/amplifications of the PIK3CA or AKT genes. AKT pathway activation is associated with poor prognosis and may lead to resistance to chemotherapy. Ipatasertib is advancing in clinical development including three Phase 2 trials in patients with breast cancer, gastric cancer and prostate cancer.

- See more at: http://www.arraybiopharma.com/product-pipeline/other-compounds/ipatasertib-gdc-0068/#sthash.2neTfebj.dpuf